The HER‐2/ neu Oncogene in Breast Cancer: Prognostic Factor, Predictive Factor, and Target for Therapy

10.1126/science.3289120

10.1016/0046-8177(94)90083-3

10.1006/scbi.1995.0016

10.1126/science.3798106

Berger MS, 1988, Correlation of c‐erb B2 gene amplification and protein expression in human breast carcinoma with nodal status and nuclear grading., Cancer Res, 48, 1238

10.1056/NEJM198811103191902

Heintz NH, 1990, Amplification of the c‐erb B‐2 oncogene in prognosis of breast adenocarcinoma., Arch Pathol Lab Med, 114, 160

10.1002/1097-0142(19900415)65:8<1794::AID-CNCR2820650821>3.0.CO;2-Y

Borg A, 1990, HER‐2/neu amplification predicts poor survival in node‐positive breast cancer., Cancer Res, 50, 4332

10.1200/JCO.1990.8.1.103

Battifora H, 1991, Immunohistochemical assay of neu/c‐erb B‐2 oncogene product in paraffin‐embedded tissues in early breast cancer: Retrospective follow‐up study of 245 stage I and II cases., Modern Pathol, 4, 466

10.1002/ijc.2910490504

Clark GM, 1991, Follow‐up study of HER‐2/neu amplification in primary breast cancer., Cancer Res, 51, 944

10.1038/bjc.1991.101

McCann AH, 1991, Prognostic significance of C‐erb B2 and estrogen receptor status in human breast cancer., Cancer Res, 51, 3296

10.1002/path.1711630205

10.1002/ijc.2910490109

10.1038/bjc.1991.103

10.1038/bjc.1991.102

Paterson MC, 1991, Correlation between C‐erb B2 amplification and risk of recurrent disease in node‐negative breast cancer., Cancer Res, 51, 556

10.1200/JCO.1992.10.7.1044

Molina R, 1992, Expression of HER‐2/neu oncoprotein in breast cancer: a comparison of immunohistochemical and western blot techniques., Anticancer Res, 12, 1965

10.1002/1097-0142(19920615)69:12<2953::AID-CNCR2820691214>3.0.CO;2-U

10.1200/JCO.1992.10.4.599

10.1002/1097-0142(19920815)70:4<770::AID-CNCR2820700409>3.0.CO;2-U

Tiwari RK, 1992, HER‐2/neu amplification and overexpression in primary human breast cancer is associated with early metastasis., Anticancer Res, 12, 419

10.1200/JCO.1992.10.7.1049

10.1038/bjc.1993.114

Press MF, 1993, Her‐2/neu expression in node‐negative breast cancer: direct tissue quantification by computerized image analysis and association of overexpression with increased risk of recurrent disease., Cancer Res, 53, 4960

10.1200/JCO.1993.11.10.1936

Descotes F, 1993, Human breast cancer: correlation study between Her‐2/neu amplification and prognostic factors in an unselected population., Anticancer Res, 13, 119

Giai M, 1994, Prognostic and predictive relevance of C‐erb B2 and ras expression in node‐positive and negative breast cancer., Anticancer Res, 14, 1441

10.1056/NEJM199405053301802

10.1002/1097-0142(19940501)73:9<2359::AID-CNCR2820730919>3.0.CO;2-9

10.1002/1097-0142(19941201)74:11<2956::AID-CNCR2820741111>3.0.CO;2-V

Jacquemier J, 1994, Breast cancer response to adjuvant chemotherapy in correlation with erb B2 and p53 expression., Anticancer Res, 14, 2773

10.1097/00000658-199404000-00002

10.1002/1097-0142(19950315)75:6<1320::AID-CNCR2820750614>3.0.CO;2-C

10.1007/BF00665980

10.1016/S0046-8177(96)90072-6

10.1016/S0046-8177(96)90224-5

Hieken TJ, 1996, Her‐2/neu and p53 expression in breast cancer: valid prognostic markers when assessed by direct immunoassay, but not by immunochemistry., Proc Annu Meet Am Soc Clin Oncol, 15, 113a

10.1007/BF01806187

Dittadi R, 1997, ErbB2 assay in breast cancer: possibly improved clinical information using a quantitative method., Anticancer Res, 17, 1245

Fernandez‐Acenero MJ, 1997, Immunohistochemical expression of p53 and c‐erbB‐2 in breast carcinoma: relation with epidemiologic factors, histologic features and prognosis., Gen Diagn Pathol, 142, 289

Eissa S, 1997, Multivariate analysis of DNA ploidy, p53, c‐erbB‐2 proteins, EGFR, and steroid hormone receptors for short‐term prognosis in breast cancer., Anticancer Res, 17, 3091

10.1038/bjc.1997.283

10.1200/JCO.1997.15.8.2894

Ross JS, 1998, Multivariate analysis of prognostic factors in lymph node negative breast cancer., Mod Pathol, 11, 26a

Depowski PL, 1998, Prognostic significance of p34cdc2 cyclin dependent kinase and MIB1 overexpression, and HER‐2/neu gene amplification detected by fluorescence in‐situ hybridization in breast cancer., Mod Pathol, 11, 18A

10.1097/00000478-199104000-00002

10.1016/S0889-8588(18)30188-6

10.1093/jnci/82.12.1006

Pauletti G, 1996, Detection and quantitation of HER‐2/neu gene amplification in human breast cancer archival material using fluorescence in situ hybridization., Oncogene, 13, 63

10.1159/000333683

Allred DC, 1998, Prognostic and predictive factors in breast cancer by immunohistochemical analysis., Mod Pathol, 11, 155

10.1093/jnci/88.15.1054

10.1002/path.1711730111

10.1080/00313029400169611

Press MF, 1994, Sensitivity of Her‐2/neu antibodies in archival tissue samples: potential source of error in immunohistochemical studies of oncogene expression., Cancer Res, 54, 2771

10.1136/jcp.50.10.801

Lodato RF, 1990, Immunohistochemical evaluation of cerb B2 oncogene expression in ductal carcinoma in situ and atypical ductal hyperplasia of the breast., Mod Pathol, 3, 449

10.1016/0046-8177(92)90257-4

Zafrani B, 1994, Mammographically‐detected ductal in‐situ carcinoma of the breast analyzed with a new classification., Sem Diagn Pathol, 11, 208

10.1007/BF02306378

10.1002/1097-0142(19950415)75:8<2123::AID-CNCR2820750815>3.0.CO;2-V

10.1002/path.1711760404

10.1016/0046-8177(95)90163-9

10.1007/BF01806635

10.1016/S0344-0338(96)80205-6

Bose S, 1996, Immunophenotype of intraductal carcinoma., Arch Pathol Lab Med, 120, 81

Moreno A, 1997, Ductal carcinoma in‐situ of the breast: Correlation between histologic classification and biologic markers., Mod Pathol, 10, 1088

10.1016/S0046-8177(97)90014-9

10.1002/1097-0142(19910715)68:2<331::AID-CNCR2820680221>3.0.CO;2-X

10.1093/ajcp/96.2.243

Lilleng R, 1992, cerb B2 protein and neuroendocrine expression in intraductal carcinomas of the breast., Mod Pathol, 5, 41

Yeh I‐T, 1993, Expression of erb B2 gene in the benign and proliferative breast tissue., Surg Pathol, 5, 109

Hanna W, 1990, Distribution and patterns of staining of neu oncogene product in benign and malignant breast diseases., Mod Pathol, 3, 455

10.1002/1097-0142(19940615)73:12<2978::AID-CNCR2820731215>3.0.CO;2-5

10.1177/106689699500200305

10.1002/(SICI)1097-0142(19960201)77:3<490::AID-CNCR10>3.0.CO;2-#

Willsher PC, 1997, Male breast cancer: pathological and immunohistochemical features., Anticancer Res, 17, 2335

Bines J, 1997, C‐erb and p53 overexpression as predictors of survival in patients with male breast cancer., Proc Ann Assoc Clin Oncol, 16, 558a

10.1016/S0748-7983(96)91418-3

Dawson PJ, 1992, Immunocytochemical characterization of male breast cancer., Mod Pathol, 5, 621

10.1038/bjc.1992.22

10.1200/JCO.1995.13.5.1129

10.1016/0378-1119(94)00534-Y

10.1016/0959-8049(95)00344-4

10.1038/bjc.1995.497

Yu D, 1996, Overexpression of cerbB2/neu in breast cancer cells confers increased resistance to Taxol via mdr‐1‐independent mechanisms., Oncogene, 13, 1359

10.1200/JCO.1996.14.10.2702

10.1016/0360-3016(96)00150-2

10.1016/0959-8049(95)00568-4

Baselga J, 1997, HER‐2 overexpression and paclitaxel sensitivity in breast cancer: therapeutic implications., Oncology, 11, 43

10.1038/sj.onc.1201222

Newby JC, 1997, Expression of epidermal growth factor receptor and C‐erb B2 during the development of tamoxifen resistance in human breast cancer., Clin Cancer Res, 3, 1643

10.1002/(SICI)1097-0142(19980301)82:5<874::AID-CNCR11>3.0.CO;2-Y

10.1200/JCO.1997.15.7.2518

Elledge RM, 1998, HER‐2 expression and response to tamoxifen in estrogen receptor‐positive breast cancer: a Southwest Oncology Group study., Clin Cancer Res, 4, 7

Bianco AR, 1998, 20 year update of the Naples Gun trial of adjuvant breast cancer therapy: eveidence of interaction between c‐erb‐B2 expression and tamoxifen efficacy., Proc Am Soc Clin Oncol, 17, 97a

Ravdin PM, 1998, Initial report of the SWOG biological correlative study of c‐ERBB2 expression as a predictor of outcome in a trial comparing adjuvant CAF with Tamoxifen alone., Proc Am Soc Clin Oncol, 17, 97a

10.1002/1097-0142(19940201)73:3<652::AID-CNCR2820730324>3.0.CO;2-4

10.1038/bjc.1994.387

10.1002/jcla.1860090303

10.3109/02841869509094014

10.1002/(SICI)1097-0142(19960715)78:2<267::AID-CNCR12>3.0.CO;2-U

10.1038/bjc.1996.501

10.1007/BF01806813

10.1023/A:1005700812422

Mansour OA, 1997, Tissue in serum CerbB2 and tissue EGFR in breast carcinoma: three years follow‐up., Anti Cancer Res, 17, 3101

10.1007/BF00918679

Zhang L, 1995, Suppressed transformation and induced differentiation of Her‐2/neu—overexpressing breast cancer cells by emodin., Cancer Res, 55, 3890

10.1200/JCO.1995.13.9.2281

10.1007/BF00311556

10.1200/JCO.1996.14.3.737

10.1089/oli.1.1996.6.9

10.1038/sj.gt.3300372

Heijnen IA, 1997, The clinical studies with Fc (Gamma) R by specific antibodies and granulocyte colony‐stimulating factor‐primed neutrophils as effector cells against HER‐2/neu overexpression in breast cancer., Cancer Res, 57, 696

10.1023/A:1005798224288

Cobleigh MA, 1998, Efficacy and safety of Herceptin® (humanized anti‐human HER‐2 antibody) as a single agent in 222 women with HER2 overexpression who relapsed following chemotherapy for metastatic breast cancer., Proc Am Soc Clin Oncol, 17, 97a

Slamon D, 1998, Addition of Herceptin® (humanized anti HER2 antibody) to first line chemotherapy for HER2 overexpressing metastatic breast cancer markedly increases anticancer activity: a randomized, multinational controlled phase III trial., Proc Am Soc Clin Oncol, 17, 98a

Brossart P, 1998, Her‐2/neu‐derived peptides are tumor‐associated antigens expressed by human renal cell carcinoma lines and are recognized by in vitro induced specific cytotoxic T lymphocytes., Cancer Res, 58, 732

Disis ML, 1998, HER‐2/neu peptide vaccines elicit T cell immunity to the HER‐2/neu protein in patients with breast and ovarian cancer., Proc Am Soc Clin Oncol, 17, 97a

10.1007/BF02789219